Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance
2018 ◽
Vol 46
(9)
◽
pp. 1285-1303
◽
Keyword(s):
2017 ◽
Vol 45
(10)
◽
pp. 1049-1059
◽
Keyword(s):
Keyword(s):
2021 ◽
pp. 1-15